His ground-breaking research on glucagon-like peptide 1 (GLP-1)-based diabetes drugs has not only transformed the lives of people with type 2 diabetes, but has also earned him the coveted title of 2023 breakthrough of the year by Science Magazine
Carolina Digital Repository (University of North Carolina at Chapel Hill) 2021
Large-scale, randomized controlled trials are needed to fully establish the efficacy and safety of this approach for alcohol use disorder
A person with a history of proliferative diabetic retinopathy, a person on insulin, a person with a prior episode of pancreatitis, and a person with significant kidney impairment each have a different set of considerations, and those considerations point in different directions
Read More Examine.com BPC-157: Benefits, Side Effects, and More Provides an overview of BPC-157s potential benefits and the lack of comprehensive clinical trials